Stay updated on Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial

Sign up to get notified when there's something new on the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The page has been updated to version v2.16.5, and the previous version v2.16.4 has been removed from the content. Additionally, a significant note regarding the modernization of ClinicalTrials.gov data ingest scheduled for July 2025 has been deleted.
    Difference
    0.7%
    Check dated 2025-07-06T00:15:09.000Z thumbnail image
  2. Check
    10 days ago
    Change Detected
    Summary
    The ClinicalTrials.gov data ingest modernization has been rescheduled to July 2025, and the study GLORIOSA has been updated with new details regarding its design and locations, including a significant increase in the number of participating sites.
    Difference
    100%
    Check dated 2025-06-28T22:04:10.000Z thumbnail image
  3. Check
    25 days ago
    Change Detected
    Summary
    The web page has been updated from version v2.16.2 to v2.16.3.
    Difference
    0.4%
    Check dated 2025-06-14T12:51:30.000Z thumbnail image
  4. Check
    32 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.16.1 to version 2.16.2.
    Difference
    0.0%
    Check dated 2025-06-07T05:19:25.000Z thumbnail image
  5. Check
    39 days ago
    Change Detected
    Summary
    The web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.
    Difference
    0.8%
    Check dated 2025-05-30T23:59:16.000Z thumbnail image
  6. Check
    47 days ago
    Change Detected
    Summary
    The webpage has been updated to reflect new study locations and contact information for a clinical trial related to ovarian cancer, including the addition of several hospitals in Japan and other countries. Additionally, the study's inclusion criteria have been revised, and the previous study details regarding Mirvetuximab Soravtansine have been removed.
    Difference
    8%
    Check dated 2025-05-23T15:22:51.000Z thumbnail image

Stay in the know with updates to Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Mirvetuximab vs Bevacizumab in Ovarian Cancer Clinical Trial page.